SCHEMBL13626146

SCHEMBL13626146

COc1ccc2c(C(=O)c3ccccc3)c(CC=O)ccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 3/20 0.48
CYP1A2 P05177 4/20 0.46
KMT2A Q03164 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
MEN1 O00255 1/20 0.46
TSHR P16473 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
ALDH1A1 P00352 4/20 0.45
CYP2C19 P33261 3/20 0.45
HPGD P15428 2/20 0.45
LMNA P02545 1/20 0.45
PGR P06401 1/20 0.45
CYP2D6 P10635 1/20 0.45
SLC6A2 P23975 1/20 0.45
PDE4A P27815 1/20 0.45
MAPK1 P28482 1/20 0.45
HRH1 P35367 1/20 0.45
HTT P42858 1/20 0.45
SLC6A3 Q01959 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13626837 0.91 MTNR1A (0.49) MTNR1ACYP1A2KMT2ACYP3A4CYP2C9
SCHEMBL13626145 0.87 MTNR1A (0.52) MTNR1ACYP1A2KMT2ACYP3A4CYP2C9
SCHEMBL13612562 0.85 PTGS1 (0.52) MTNR1ACYP1A2KMT2ACYP3A4CYP2C9
SCHEMBL13626832 0.83 MTNR1A (0.65) MTNR1ACYP1A2KMT2ACYP3A4CYP2C9
SCHEMBL13612563 0.80 HPGD (0.48) MTNR1ACYP1A2KMT2ACYP3A4CYP2C9
SCHEMBL13612568 0.79 CYP1A2 (0.58) MTNR1ACYP1A2KMT2ACYP3A4CYP2C9
SCHEMBL13626838 0.78 MTNR1A (0.53) MTNR1ACYP1A2KMT2ACYP3A4CYP2C9
SCHEMBL3911888 0.76 MTNR1A (0.51) MTNR1ACYP1A2KMT2ACYP3A4CYP2C9
SCHEMBL7423539 0.74 MTNR1A (0.56) MTNR1ACYP1A2MTNR1BNQO2
SCHEMBL31618095 0.74 MTNR1A (0.56) MTNR1ACYP1A2MTNR1BNQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281154-A1 Ophthalmic Compositions for Treating Ocular Hypertension MERCK SHARP & DOHME CORP. 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281154-A1 Ophthalmic Compositions for Treating Ocular Hypertension KCNN1, KCNN3, KCNN2 MTNR1A 357/4885CYP1A2 3909/4885KMT2A 2607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.